Takhzyro
Takhzyro ingredients
| Active ingredient | Strength |
|---|---|
| Lanadelumab | 300 mg/2mL, 150 mg/mL |
What Takhzyro is used for
The FDA lists the approved uses on the official label (below). In the EU, lanadelumab is approved as Takhzyro for:
Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Takhzyro
- Generic name
- Lanadelumab-flyo
- Made by
- Takeda Pharmaceuticals America, Inc.
- Forms
- Solution
- Given
- Subcutaneous
- Drug class
- Plasma Kallikrein Inhibitor
- FDA approval
- Biologic licence (BLA) BLA761090
- On the US market since
- 2022
Official information
- MedlinePlus drug information (search for Lanadelumab-flyo)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Takhzyro?
Takhzyro (Lanadelumab-flyo) is a specialist medicine made by Takeda Pharmaceuticals America, Inc., approved by the US FDA.
What are the ingredients of Takhzyro?
Takhzyro contains Lanadelumab (300 mg/2mL, 150 mg/mL).
Is Takhzyro approved in Europe?
The same active substance is approved in the EU as Takhzyro.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA